Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P160043/S096

Resolute Onyx Zotarolimus-Eluting Coronary Stent Systems

Medtronic Vascular · Decision date Oct 16, 2026

MEDTECHLEDGER EXPLANATIONP160043/S096

What did the FDA decide?

The FDA recorded a 30-Day Notice decision, OK30, dated 2026-10-16 for supplement P160043/S096 to Medtronic Vascular's Resolute Onyx Zotarolimus-Eluting Coronary Stent Systems, a coronary drug-eluting stent under product code NIQ in the cardiovascular specialty. The supplement reason is listed as a process change involving manufacturer, sterilizer, packager or supplier.

The recorded statement describes changing the point of finished device test sample collection. This is a manufacturing and testing logistics change within the existing PMA, not a new approval of the stent system, and the source does not identify which facility, test, or sampling step is affected. No supporting documents were included, so the specific procedural details and any FDA review basis remain unknown.

Whether the revised collection point alters test representativeness or release criteria cannot be determined from the available fields, which is the main unresolved question for quality and regulatory readers.

FDA approval order statement

changing the point of finished device test sample collection
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Oct 16, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P160043/S096
Regulatory pathway
PMA supplement
Product code
NIQ
Decision code
OK30
Decision date
Oct 16, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Coronary drug-eluting stent.

Product code
NIQ
FDA device class
3

For the original device and its historical approval scope, see PMA P160043. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P160043 · Original PMA

    RESOLUTE ONYX ZOTAROLIMUS-ELUTING CORONARY STENT SYSTEM

  2. P160043/S096 received

    Application receipt date recorded by FDA.

  3. P160043/S096 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P160043. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P160043

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic VascularPMA approvalApr 28, 2017FDA

Explore the linked device profile

Other records with product code NIQ

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic Vascular

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
3576 Unocal Pl., Santa Rosa, CA, 95403

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records